GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kangmei Pharmaceutical Co Ltd (SHSE:600518) » Definitions » Stock Based Compensation

Kangmei Pharmaceutical Co (SHSE:600518) Stock Based Compensation : ¥0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Kangmei Pharmaceutical Co Stock Based Compensation?

Kangmei Pharmaceutical Co's Stock Based Compensation for the three months ended in Mar. 2024 was ¥0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0 Mil.


Kangmei Pharmaceutical Co Stock Based Compensation Historical Data

The historical data trend for Kangmei Pharmaceutical Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kangmei Pharmaceutical Co Stock Based Compensation Chart

Kangmei Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kangmei Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kangmei Pharmaceutical Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.


Kangmei Pharmaceutical Co Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Kangmei Pharmaceutical Co's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Kangmei Pharmaceutical Co (SHSE:600518) Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Taike Road, Xiameilin, Futian District, Shenzhen, CHN, 518000
Kangmei Pharmaceutical Co Ltd is a pharmaceutical company engaged in the manufacturing, research and marketing of herbal medicine and chemical raw materials.
Executives
Xu Dong Jin Director
Li Jian Hua senior management
Qiu Xi Wei Director
Wang Min senior management
Peng Qin senior management
Ma Xing Tian Director
Lin Guo Xiong senior management
Zhuang Yi Qing senior management
Wen Shao Sheng Supervisors

Kangmei Pharmaceutical Co (SHSE:600518) Headlines

No Headlines